The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection

Helicobacter

Volumn 12, Issue 1, 2007, Pages 1-15

  De Vries, A C ^a   Haringsma, J ^a   Kuipers, E J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Detection; Premalignant gastric lesions; Surveillance; Treatment

Indexed keywords

ASCORBIC ACID; BETA CAROTENE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FOLIC ACID; GASTRIN; NONSTEROID ANTIINFLAMMATORY AGENT; PEPSINOGEN; ROFECOXIB;

ATROPHIC GASTRITIS; BACTERIAL COLONIZATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER THERAPY; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIET SUPPLEMENTATION; DISEASE CLASSIFICATION; DYSPLASIA; ENDOSCOPIC MUCOSAL RESECTION; ERADICATION THERAPY; FLUORESCENCE SPECTROSCOPY; FOLLOW UP; GASTRECTOMY; GASTROINTESTINAL SYMPTOM; GASTROSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; INTESTINE METAPLASIA; KIDNEY DISEASE; META ANALYSIS; NON INVASIVE MEASUREMENT; PRECANCER; PRIORITY JOURNAL; RAMAN SPECTROMETRY; REVIEW; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; STOMACH CARCINOGENESIS; STOMACH CARCINOMA; STOMACH LESION; SYSTEMATIC REVIEW;

ANTI-BACTERIAL AGENTS; GASTRIC MUCOSA; GASTRITIS, ATROPHIC; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METAPLASIA; SENTINEL SURVEILLANCE; STOMACH NEOPLASMS;

HELICOBACTER PYLORI;

EID: 33846211765     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2007.00475.x     Document Type: Review

References (162)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2 0, Lyon, France: IARC Press, 2004.
2. Bowles MJ, Benjamin IS. ABC of the upper gastrointestinal tract. Cancer of the stomach and pancreas. BMJ 2001;323:1413-6.
3. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49.
4. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49:347-53.
5. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735-40.
6. Meining A, Morgner A, Miehlke S, Bayerdorffer E, Stolte M. Atrophy-metaplasia-dysplasia-carcinoma sequence in the stomach: a reality or merely an hypothesis? Best Pract Res Clin Gastroenterol 2001;15:983-98.
7. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
8. Miehlke S, Hackelsberger A, Meining A, et al. Severe expression of corpus gastritis is characteristic in gastric cancer patients infected with Helicobacter pylori. Br J Cancer 1998;78:263-6.
9. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.
10. Strickland RG, Mackay IR. A reappraisal of the nature and significance of chronic atrophic gastritis. Am J Dig Dis 1973 May;18:426-40.
11. Whitehead R. The classification of chronic gastritis: current status. J Clin Gastroenterol 1995;21 (Suppl. 1):S131-4.
12. Whitehead R, Truelove SC, Gear MW. The histological diagnosis of chronic gastritis in fibreoptic gastroscope biopsy specimens. J Clin Pathol 1972;25:1-11.
13. Correa P, Yardley JH. Grading and classification of chronic gastritis: one American response to the Sydney system. Gastroenterology 1992;102:355-9.
14. Rubin CE. Are there three types of Helicobacter pylori gastritis? Gastroenterology 1997;112:2108-10.
15. El-Zimaity HM, Graham DY, al-Assi MT, et al. Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Hum Pathol 1996;27:35-41.
16. Offerhaus GJ, Price AB, Haot J, et al. Observer agreement on the grading of gastric atrophy. Histopathology 1999;34:320-5.
17. Chen XY, van Der Hulst RW, van der Bruno MJEA, et al. Interobserver variation in the histopathological scoring of Helicobacter pylori related gastritis. J Clin Pathol 1999;52:612-5.
18. van Grieken NC, Weiss MM, Meijer GA, et al. Rapid quantitative assessment of gastric corpus atrophy in tissue sections. J Clin Pathol 2001;54:63-9.
19. Ruiz B, Garay J, Johnson W, et al. Morphometric assessment of gastric antral atrophy: comparison with visual evaluation. Histopathology 2001;39:235-42.
20. Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther 2002 July;16:1249-59.
21. Jass JR, Filipe MI. The mucin profiles of normal gastric mucosa, intestinal metaplasia and its variants and gastric carcinoma. Histochem J 1981;13:931-9.
22. Schlemper RJ, Itabashi M, Kato Y, et al. Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists. Lancet 1997;349:1725-9.
23. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000;47:251-5.
24. Dixon MF. Gastrointestinal epithelial neoplasia: Vienna revisited. Gut 2002;51:130-1.
25. Rugge M, Correa P, Dixon MF, et al. Gastric dysplasia: the Padova international classification. Am J Surg Pathol 2000;24:167-76.
26. El-Zimaity HM, Ota H, Graham DY, Akamatsu T, Katsuyama T. Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer 2002;94:1428-36.
27. Sipponen P, Kimura K. Intestinal metaplasia, atrophic gastritis and stomach cancer: trends over time. Eur J Gastroenterol Hepatol 1994;6:S79-S83.
28. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995;345:1525-8.
29. Miwa H, Go MF, Sato NH. Pylori and gastric cancer: the Asian enigma. Am J Gastroenterol 2002;97:1106-12.
30. Weck MN, Brenner H. Prevalence of chronic atrophic gastritis in different parts of the world. Cancer Epidemiol Biomarkers Prev 2006;15:1083-94.
31. Sipponen P, Helske T, Jarvinen P, Hyvarinen H, Seppala K, Siurala M. Fall in the prevalence of chronic gastritis over 15 years: analysis of outpatient series in Finland from 1977, 1985, and 1992. Gut 1994;35:1167-71.
32. Petersson F, Borch K, Franzen LE. Prevalence of subtypes of intestinal metaplasia in the general population and in patients with autoimmune chronic atrophic gastritis. Scand J Gastroenterol 2002;37:262-6.
33. Borch K, Jonsson KA, Petersson F, Redeen S, Mardh S, Franzen LE. Prevalence of gastroduodenitis and Helicobacter pylori infection in a general population sample: relations to symptomatology and life-style. Dig Dis Sci 2000;45:1322-9.
34. Asaka M, Sugiyama T, Nobuta A, Kato M, Takeda H, Graham DY. Atrophic gastritis and intestinal metaplasia in Japan: results of a large multicenter study. Helicobacter 2001;6:294-9.
35. Lauwers GY, Riddell RH. Gastric epithelial dysplasia. Gut 1999;45:784-90.
36. Yamada H, Ikegami M, Shimoda T, Takagi N, Maruyama M. Long-term follow-up study of gastric adenoma/dysplasia. Endoscopy 2004;36:390-6.
37. Andersson AP, Lauritsen KB, West F, Johansen A. Dysplasia in gastric mucosa: prognostic significance. Acta Chir Scand 1987;153:29-31.
38. Armbrecht U, Stockbrugger RW, Rode J, Menon GG, Cotton PB. Development of gastric dysplasia in pernicious anaemia: a clinical and endoscopic follow up study of 80 patients. Gut 1990;31:1105-9.
39. Bearzi I, Brancorsini D, Santinelli A, Rezai B, Mannello B, Ranaldi R. Gastric dysplasia: a ten-year follow-up study. Pathol Res Pract 1994;190:61-8.
40. Borch K. Epidemiologic, clinicopathologic, and economic aspects of gastroscopic screening of patients with pernicious anemia. Scand J Gastroenterol 1986;21:21-30.
41. Cheli R, Santi L, Ciancamerla G, Canciani G. A clinical and statistical follow-up study of atrophic gastritis. Am J Dig Dis 1973;18:1061-5.
42. Coma del Corral MJ, Pardo-Mindan FJ, Razquin S, Ojeda C. Risk of cancer in patients with gastric dysplasia. Follow-up study of 67 patients. Cancer 1990;65:2078-85.
43. Di GC, Morandi P, De Fante R, GC. Gastric dysplasia. A follow-up study. Am J Gastroenterol 1993;88:1714-9.
44. Dinis-Ribeiro M, Lopes C, da Costa-Pereira A, et al. A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. J Clin Pathol 2004;57:177-82.
45. Ectors N, Dixon MF. The prognostic value of sulphomucin positive intestinal metaplasia in the development of gastric cancer. Histopathology 1986;10:1271-7.
46. El-Zimaity HM, Ramchatesingh J, Saeed MA, Graham DY. Gastric intestinal metaplasia: subtypes and natural history. J Clin Pathol 2001;54:679-83.
47. Farinati F, Di Rugge MMF, Valiante F, Baffa R. Early and advanced gastric cancer in the follow-up of moderate and severe gastric dysplasia patients. A prospective study. I.G.G.E.D. - Interdisciplinary Group on Gastric Epithelial Dysplasia. Endoscopy 1993;25:261-4.
48. Farini R, Farinati F, Di Leandro GMF, Cecchetto A, Naccarato R. Gastric epithelial dysplasia in relapsing and nonrelapsing gastric ulcer. Am J Gastroenterol 1982;77:844-53.
49. Farini R, Pagnini CA, Di Farinati FMF, et al. Is mild gastric epithelial dysplasia an indication for follow-up? J Clin Gastroenterol 1983;5:307-10.
50. Fertitta AM, Comin U, Terruzzi V, et al. Clinical significance of gastric dysplasia: a multicenter follow-up study. Gastrointestinal Endoscopic Pathology Study Group. Endoscopy 1993;25:265-8.
51. Filipe MI, Munoz N, Matko I, et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 1994;57:324-9.
52. Findley JW Jr, Kirsner JB, Palme WL. Atrophic gastritis; a follow-up study of 100 patients. Gastroenterology 1950;16:347-53.
53. Irie K, Fujita K, Okuna T, et al. The follow-up study on the precancerous conditions of the stomach. Gastroenterol Jap 1970;5.
54. Koch HK, Oehlert M, Oehlert W. An evaluation of gastric dysplasia in the years 1986 and 1987. Pathol Res Pract 1990;186:80-4.
55. Kokkola A, Haapiainen R, Laxen F, et al. Risk of gastric carcinoma in patients with mucosal dysplasia associated with atrophic gastritis: a follow up study. J Clin Pathol 1996;49:979-84.
56. Kokkola A, Sjoblom SM, Haapiainen R, Sipponen P, Puolakkainen P, Jarvinen H. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand J Gastroenterol 1998;33:88-92.
57. Lahner E, Caruana P, D'Ambra G, et al. First endoscopic-histologic follow-up in patients with body-predominant atrophic gastritis: when should it be done? Gastrointest Endosc 2001;53:443-8.
58. Lahner E, Bordi C, Cattaruzza MS, et al. Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. Aliment Pharmacol Ther 2005;22:471-81.
59. Lansdown M, Quirke P, Dixon MF, Axon AT, Johnston D. High grade dysplasia of the gastric mucosa: a marker for gastric carcinoma. Gut 1990;31:977-83.
60. Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut 1991;32:1110-3.
61. Rugge M, Di Farinati FMF, Baffa R, Valiante F, Cardin F. Gastric epithelial dysplasia: a prospective multicenter follow-up study from the Interdisciplinary Group on Gastric Epithelial Dysplasia. Hum Pathol 1991;22:1002-8.
62. Rugge M, Farinati F, Baffa R, et al. Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology 1994;107:1288-96.
63. Rugge M, Di Cassaro MMF, Leo G, et al. The long term outcome of gastric non-invasive neoplasia. Gut 2003 August;52:1111-6.
64. Sakaki N, Arakawa T, Katou H, et al. Relationship between progression of gastric mucosal atrophy and Helicobacter pylori infection: retrospective long-term endoscopic follow-up study. J Gastroenterol 1997;32:19-23.
65. Sakaki N, Kozawa H, Egawa N, Tu Y, Sanaka M. Ten-year prospective follow-up study on the relationship between Helicobacter pylori infection and progression of atrophic gastritis, particularly assessed by endoscopic findings. Aliment Pharmacol Ther 2002;16:198-203.
66. Saraga EP, Gardiol D, Costa J. Gastric dysplasia. A histological follow-up study. Am J Surg Pathol 1987;11:788-96.
67. Silva S, Filipe MI, Pinho A. Variants of intestinal metaplasia in the evolution of chronic atrophic gastritis and gastric ulcer. A follow up study. Gut 1990;31:1097-104.
68. Siurala M, Varis K, Wiljasalo M. Studies of patients with atrophic gastritis: a 10-15-year follow-up. Scand J Gastroenterol 1966;1:40-8.
69. Siurala M, Lehtola J, Ihamaki T. Atrophic gastritis and its sequelae. Results of 19-23 years' follow-up examinations. Scand J Gastroenterol 1974;9:441-6.
70. Sjoblom SM, Sipponen P, Jarvinen H. Gastroscopic follow up of pernicious anaemia patients. Gut 1993;34:28-32.
71. Tatsuta M, Iishi H, Nakaizumi A, et al. Fundal atrophic gastritis as a risk factor for gastric cancer. Int J Cancer 1993;53:70-4.
72. Testoni PA, Masci E, Marchi R, Guslandi M, Ronchi G, Tittobello A. Gastric cancer in chronic atrophic gastritis. Associated gastric ulcer adds no further risk. J Clin Gastroenterol 1987;9:298-302.
73. Walker IR, Strickland RG, Ungar B, Mackay IR. Simple atrophic gastritis and gastric carcinoma. Gut 1971;12:906-11.
74. Whiting JL, Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JW. The long term results of endoscopic surveillance of premalignant gastric lesions. Gut 2002;50:378-81.
75. You WC, Li JY, Blot WJ, et al. Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. Int J Cancer 1999;83:615-9.
76. Cassaro M, Rugge M, Gutierrez O, Leandro G, Graham DY, Genta RM. Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol 2000;95:1431-8.
77. Inoue M, Tajima K, Kobayashi S, et al. Protective factor against progression from atrophic gastritis to gastric cancer - data from a cohort study in Japan. Int J Cancer 1996;66:309-14.
78. Sipponen P, Kekki M, Haapakoski J, Ihamaki T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 1985;35:173-7.
79. Genta RM, Rugge M. Review article: pre-neoplastic states of the gastric mucosa - a practical approach for the perplexed clinician. Aliment Pharmacol Ther 2001;15 (Suppl. 1):43-50.
80. Fennerty MB. Gastric intestinal metaplasia on routine endoscopic biopsy. Gastroenterology 2003;125:586-90.
81. Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005 June;54:764-8.
82. Rugge M, Leandro G, Di Farinati FMF, et al. Gastric epithelial dysplasia. How clinicopathologic background relates to management. Cancer 1995;76:376-82.
83. Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53:1244-9.
84. Weinstein WM, Goldstein NS. Gastric dysplasia and its management. Gastroenterology 1994;107:1543-5.
85. Lee KJ, Inoue M, Otani T, Iwasaki M, Sasazuki S, Tsugane S. Gastric cancer screening and subsequent risk of gastric cancer: A large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer 2005.
86. Oshima A, Hirata N, Ubukata T, Umeda K, Fujimoto I. Evaluation of a mass screening program for stomach cancer with a case-control study design. Int J Cancer 1986;38:829-33.
87. Fukao A, Tsubono Y, Tsuji I, Hisamichi S, Sugahara N, Takano A. The evaluation of screening for gastric cancer in Miyagi Prefecture, Japan: a population-based case-control study. Int J Cancer 1995;60:45-8.
88. Hisamichi S, Sugawara N, Fukao A. Effectiveness of gastric mass screening in Japan. Cancer Detect Prev 1988;11:323-9.
89. You WC, Ma JL, Liu W, et al. Blood type and family cancer history in relation to precancerous gastric lesions. Int J Epidemiol 2000;29:405-7.
90. La VC, Negri E, Franceschi S, Gentile A. Family history and the risk of stomach and colorectal cancer. Cancer 1992;70:50-5.
91. Ley C, Mohar A, Guarner J, et al. Screening markers for chronic atrophic gastritis in Chiapas. Mexico Cancer Epidemiol Biomarkers Prev 2001;10:107-12.
92. Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JI. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology 1982;83:204-9.
93. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, et al. Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma. Neoplasia 2004;6:449-56.
94. Pasechnikov VD, Chukov SZ, Kotelevets SM, Mostovov AN, Mernova VP, Polyakova MB. Invasive and non-invasive diagnosis of Helicobacter pylori-associated atrophic gastritis: a comparative study. Scand J Gastroenterol 2005;40:297-301.
95. Vaananen H, Vauhkonen M, Helske T, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 2003;15:885-91.
96. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969;3:87-97.
97. Update on the paris classification of superficial neoplastic lesions in the digestive tract. Endoscopy 2005 June;37:570-8.
98. Carpenter HA, Talley NJ. Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis. Gastroenterology 1995;108:917-24.
99. Redeen S, Petersson F, Jonsson KA, Borch K. Relationship of gastroscopic features to histological findings in gastritis and Helicobacter pylori infection in a general population sample. Endoscopy 2003;35:946-50.
100. Lin BR, Shun CT, Wang TH, Lin JT. Endoscopic diagnosis of intestinal metaplasia of stomach - accuracy judged by histology. Hepatogastroenterology 1999;46:162-6.
101. Sauerbruch T, Schreiber MA, Schussler P, Permanetter W. Endoscopy in the diagnosis of gastritis. Diagnostic value of endoscopic criteria in relation to histological diagnosis. Endoscopy 1984;16:101-4.
102. Meshkinpour H, Orlando RA, Arguello JF, DeMicco MP. Significance of endoscopically visible blood vessels as an index of atrophic gastritis. Am J Gastroenterol 1979;71:376-9.
103. Nakagawa S, Kato M, Shimizu Y, et al. Relationship between histopathologic gastritis and mucosal microvascularity: observations with magnifying endoscopy. Gastrointest Endosc 2003;58:71-5.
104. Yagi K, Nakamura A, Sekine A. Comparison between magnifying endoscopy and histological, culture and urease test findings from the gastric mucosa of the corpus. Endoscopy 2002;34:376-81.
105. Kim S, Harum K, Ito M, Tanaka S, Yoshihara M, Chayama K. Magnifying gastroendoscopy for diagnosis of histologic gastritis in the gastric antrum. Dig Liver Dis 2004;36:286-91.
106. Guelrud M, Herrera I, Essenfeld H, Castro J, Antonioli DA. Intestinal metaplasia of the gastric cardia: a prospective study with enhanced magnification endoscopy. Am J Gastroenterol 2002;97:584-9.
107. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, et al. Magnification chromoendoscopy for the diagnosis of gastric intestinal metaplasia and dysplasia. Gastrointest Endosc 2003;57:498-504.
108. Tajiri H, Doi T, Endo H, et al. Routine endoscopy using a magnifying endoscope for gastric cancer diagnosis. Endoscopy 2002;34:772-7.
109. Yao K. Gastric microvascular architecture as visualized by magnifying endoscopy: body and antral mucosa without pathologic change demonstrate two different patterns of microvascular architecture. Gastrointest Endosc 2004;59:596-7.
110. Shaw D, Blair V, Framp A, et al. Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy? Gut 2005;54:461-8.
111. Nakayoshi T, Tajiri H, Matsuda K, Kaise M, Ikegami M, Sasaki H. Magnifying endoscopy combined with narrow band imaging system for early gastric cancer: correlation of vascular pattern with histopathology (including video). Endoscopy 2004;36:1080-4.
112. Sumiyama K, Kaise M, Nakayoshi T, et al. Combined use of a magnifying endoscope with a narrow band imaging system and a multibending endoscope for en bloc EMR of early stage gastric cancer. Gastrointest Endosc 2004;60:79-84.
113. Ohkawa A, Miwa H, Namihisa A, et al. Diagnostic performance of light-induced fluorescence endoscopy for gastric neoplasms. Endoscopy 2004;36:515-21.
114. Mayinger B, Jordan M, Horbach T, et al. Evaluation of in vivo endoscopic autofluorescence spectroscopy in gastric cancer. Gastrointest Endosc 2004;59:191-8.
115. Kobayashi M, Tajiri H, Seike E, et al. Detection of early gastric cancer by a real-time autofluorescence imaging system. Cancer Lett 2001;165:155-9.
116. Abe S, Izuishi K, Tajiri H, Kinoshita T, Matsuoka T. Correlation of in vitro autofluorescence endoscopy images with histopathologic findings in stomach cancer. Endoscopy 2000;32:281-6.
117. Anagnostopoulos GK, Ragunath K, Fortun PJ, Yao K. Identifying Helicobacter pylori-associated gastritis, gastric atrophy and intestinal metaplasia with magnification endoscopy and adaptive index of haemoglobin enhancement technique. Dig Liver Dis 2005;37:980-1.
118. Ortner MA, Ebert B, Hein E, et al. Time gated fluorescence spectroscopy in Barrett's oesophagus. Gut 2003;52:28-33.
119. Kendall C, Stone N, Shepherd N, et al. Raman spectroscopy, a potential tool for the objective identification and classification of neoplasia in Barrett's oesophagus. J Pathol 2003;200:602-9.
120. Lovat LB, Johnson K, Mackenzie GD, et al. Elastic scattering spectroscopy accurately detects high grade dysplasia and cancer in Barrett's oesophagus. Gut 2006.
121. Haringsma J. Finding the needles in the haystack. Gastrointest Endosc 2006;64:186-7.
122. You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006;98:974-83.
123. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-8.
124. Gisbert JP, Blanco M, Pajares JM. [Effect of Helicobacter pylori eradication on histological lesions of gastric mucosa. An 18-month follow-up study]. Rev Clin Esp 2000;200:480-4.
125. Kamada T, Haruma K, Hata J, et al. The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. Aliment Pharmacol Ther 2003;18:245-52.
126. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004;53:12-20.
127. Leri O, Mastropasqua M, Scopelliti G, et al. [The effects of eradication therapy in patients with chronic atrophic gastritis and seropositivity for anti-HP antibodies and histological negativity for Helicobacter pylori]. Clin Ter 1999;150:343-6.
128. Ley C, Mohar A, Guarner J, et al. Helicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial. Cancer Epidemiol Biomarkers Prev 2004;13:4-10.
129. Mera R, Fontham ET, Bravo LE, et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005;54:1536-40.
130. Miwa H, Hirai S, Nagahara A, et al. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. Aliment Pharmacol Ther 2000;14:317-24.
131. Ohkusa T, Takashimizu I, Fujiki K, et al. Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial. Ann Intern Med 1998;129:712-5.
132. Schenk BE, Kuipers EJ, Nelis GF, et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000;46:615-21.
133. Sung JJ, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000;119:7-14.
134. Witteman EM, Mravunac M, Becx MJ, et al. Improvement of gastric inflammation and resolution of epithelial damage one year after eradication of Helicobacter pylori. J Clin Pathol 1995;48:250-6.
135. Zhou L, Sung JJ, Lin S, et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin Med J (Engl) 2003;116:11-4.
136. Take S, Mizuno M, Ishiki K, et al. The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 2005;100:1037-42.
137. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-94.
138. Nardone G, Rocco A. Chemoprevention of gastric cancer: role of COX-2 inhibitors and other agents. Dig Dis 2004;22:320-6.
139. Cao DZ, Sun WH, Ou XL, et al. Effects of folic acid on epithelial apoptosis and expression of Bcl-2 and p53 in premalignant gastric lesions. World J Gastroenterol 2005;11:1571-6.
140. Zhu S, Mason J, Shi Y, et al. The effect of folic acid on the development of stomach and other gastrointestinal cancers. Chin Med J (Engl) 2003;116:15-9.
141. Zullo A, Rinaldi V, Hassan C, et al. Ascorbic acid and intestinal metaplasia in the stomach: a prospective, randomized study. Aliment Pharmacol Ther 2000;14:1303-9.
142. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 2004;364:1219-28.
143. Nardone G, Rocco A, Vaira D, et al. Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H pylori-related gastric carcinogenesis. J Pathol 2004;202:305-12.
144. Sung JJ, Leung WK, Go MY, et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol 2000;157:729-35.
145. Zhou XM, Wong BC, Fan XM, et al. Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak. Carcinogenesis 2001;22:1393-7.
146. Jiang XH, Lam SK, Lin MC, et al. Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-beta (1)-dependent pathway. Oncogene 2002;21:6113-22.
147. Wong BC, Jiang X, Fan XM, et al. Suppression of RelA/p65 nuclear translocation independent of IkappaB-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer. Oncogene 2003;22:1189-97.
148. Wu J, Xia HH, Tu SP, et al. 15-Lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer. Carcinogenesis 2003;24:243-7.
149. Hu PJ, Yu J, Zeng ZR, et al. Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004;53:195-200.
150. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003;95:1784-91.
151. Leung WK, Ng EK, Chan FK, et al. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. Clin Cancer Res 2006;12:4766-72.
152. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-9.
153. Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer 2002;5:1-5.
154. Miyamoto S, Muto M, Hamamoto Y, et al. A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasms. Gastrointest Endosc 2002;55:576-81.
155. Gotoda T. Endoscopic resection of early gastric cancer: the Japanese perspective. Curr Opin Gastroenterol 2006;22:561-9.
156. Choi IJ, Kim CG, Chang HJ, Kim SG, Kook MC, Bae JM. The learning curve for EMR with circumferential mucosal incision in treating intramucosal gastric neoplasm. Gastrointest Endosc 2005;62:860-5.
157. Ohkuwa M, Hosokawa K, Boku N, Ohtu A, Tajiri H, Yoshida S. New endoscopic treatment for intramucosal gastric tumors using an insulated-tip diathermic knife. Endoscopy 2001;33:221-6.
158. Miyamoto S, Muto M, Hamamoto Y, et al. A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasms. Gastrointest Endosc 2002;55:576-81.
159. Yamamoto H, Kawata H, Sunada K, et al. Success rate of curative endoscopic mucosal resection with circumferential mucosal incision assisted by submucosal injection of sodium hyaluronate. Gastrointest Endosc 2002;56:507-12.
160. Ono H, Kondo H, Gotoda T, et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut 2001;48:225-9.
161. Wang YP, Bennett C, Pan T. Endoscopic mucosal resection for early gastric cancer. Cochrane Database Syst Rev 2006;(1):CD004276.
162. Nasu J, Doi T, Endo H, Nishina T, Hirasaki S, Hyodo I. Characteristics of metachronous multiple early gastric cancers after endoscopic mucosal resection. Endoscopy 2005;37:990-3.